期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 20, 期 3, 页码 361-373出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2016.1091448
关键词
4-1BB; autoimmune disease; cancer; T cells; therapy
资金
- National Cancer Center, Korea [NCC-1310430-2]
- National Research Foundation of Korea [NRF-2005-0093837]
- Korea Drug Development Fund [KDDF-201408-11]
- Korea Institute for Advancement of Technology under their International Collaborative Research and Development Program [KIAT-N0000901]
Introduction: 4-1BB (CD137) is an important T-cell stimulating molecule. The 4-1BB mAb or its variants have shown remarkable therapeutic activity against autoimmunity, viral infections, and cancer. Antibodies to 4-1BB have recently entered clinical trials for the treatment of cancer with favorable toxicity profile. In this article, we present a review documenting the efficacy and pitfalls of 4-1BB therapy.Areas covered: An extensive literature search has been made on 4-1BB, spanning two decades, and a comprehensive report is presented here highlighting the origins, biological effects, therapeutic potential, and mechanistic basis of targeting 4-1BB as well as the side effects associated with such therapy.Expert opinion: Research so far indicates that 4-1BB is highly protective against various pathological conditions including cancer. However, a few important side effects of 4-1BB therapy such as liver toxicity, thrombocytopenia, anemia, and suppressive effects on certain immune competent cells should be taken into consideration before it is used for human therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据